Want to join the conversation?
$ABBV expects adjusted EPS of $1.18-1.20 for 3Q16 and this excludes roughly $0.16 of specified items and non-cash amortization and includes the dilutive impact of Stemcentrx and the Boehringer Ingelheim collaboration. The company expects high single-digit operational sales growth, excluding a modest negative ForEx impact in 3Q16.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.